Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,626 | 286 | 1,330 |
| Samples | 1,204 | 241 | 955 |
| Peptides | 941 | 182 | 806 |
Function
LPA · Lipoprotein(a)
The protein encoded by this gene is a serine proteinase that inhibits the activity of tissue-type plasminogen activator I. The encoded protein constitutes a substantial portion of lipoprotein(a) and is proteolytically cleaved, resulting in fragments that attach to atherosclerotic lesions and promote thrombogenesis. Elevated plasma levels of this protein are linked to atherosclerosis. Depending on the individual, the encoded protein contains 2-43 copies of kringle-type domains. The allele represented here contains 15 copies of the kringle-type repeats and corresponds to that found in the reference genome sequence. [provided by RefSeq, Dec 2009].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000316300 | P08519 | 1,626 | 941 |
Gene Properties
Recurrent Mutations
All 1040 amino-acid changes on canonical ENST00000316300 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LPA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LPA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Melanoma | 31/210 15% | 192/1899 10% |
| Non-Small Cell Lung Carcinoma | 50/304 16% | 85/1390 6% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 9/42 21% | 39/612 6% |
| Oral Cavity Carcinoma | 3/54 6% | 0/0 0% |
| Acute Myeloid Leukemia | 5/90 6% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 37/810 5% |
| Other Solid Cancers | 6/94 6% | 68/1515 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Colorectal Carcinoma | 19/143 13% | 118/3239 4% |
| Bladder Carcinoma | 3/58 5% | 30/956 3% |
| Gastric Carcinoma | 4/74 5% | 56/1809 3% |
| Neuroendocrine Tumour | 14/154 9% | 8/577 1% |
| Cervical Carcinoma | 5/35 14% | 7/422 2% |
| Esophageal Carcinoma | 0/23 0% | 17/769 2% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 46/2550 2% |
| Ovarian Carcinoma | 5/109 5% | 16/998 2% |
| Hepatocellular Carcinoma | 2/46 4% | 40/2210 2% |
| Small Cell Lung Carcinoma | 1/9 11% | 13/752 2% |
| Head and Neck Carcinoma | 6/85 7% | 22/1574 1% |
| Rhabdomyosarcoma | 2/33 6% | 1/171 1% |
| Biliary Tract Carcinoma | 1/54 2% | 13/950 1% |
| Non-Cancerous | 3/104 3% | 9/830 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Glioma | 0/52 0% | 24/2127 1% |
| Other Sarcomas | 4/69 6% | 4/699 1% |
| Breast Carcinoma | 8/144 6% | 26/3264 1% |
| Other Blood Cancers | 8/61 13% | 19/2725 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
Mutation Distribution
Where LPA is mutated · all tissues, split by cell line vs tissue
How many mutations in LPA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 40 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,626 mutations in LPA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|